News | June 15, 2022
CCI approves sale of biosimilars portfolio of Viatris to Biocon Biologics
The proposed transaction involves the sale of the global biosimilars portfolio of Viatris to Biocon Biologics
The proposed transaction involves the sale of the global biosimilars portfolio of Viatris to Biocon Biologics
Bayer now present in four of the largest biotechnology hubs in the United States
Steinberg brings nearly three decades of experience in biopharmaceutical equity research to Prolacta's executive team.
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
OS-SiA is the industry’s first AI-enabled digital scanner that will provide real-time predictive analysis and actionable insights
JB, in its new avatar, emerges as the fastest growing pharmaceuticals company in India
The acquisition is subject to customary closing conditions and necessary regulatory approvals. The financial terms of the transaction are confidential
The integration and transition of the brands are expected to be completed by June 2022.
ICICI Direct expects revenue CAGR of 35.6% over FY22-FY24E mainly due to the consolidation of Viatris business and they expect EBITDA margin expansion of 230bps and earnings CAGR of 64.8% over FY22-FY24E
Subscribe To Our Newsletter & Stay Updated
